the 11q13-q14 amplicon: Clinicopathological correlations and potential drivers

Genes Chromosomes and Cancer

Volumn 52, Issue 4, 2013, Pages 333-355

  Wilkerson, Paul M ^a   Reis Filho, Jorge S ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTISENSE OLIGONUCLEOTIDE; CORTACTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GRB2 ASSOCIATED BINDING PROTEIN; MESSENGER RNA; ORAL CANCER OVEREXPRESSED 1 PROTEIN; P21 ACTIVATED KINASE 1; PROTEIN; ROMIDEPSIN; TAMOXIFEN; UNCLASSIFIED DRUG;

AMPLICON; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLADDER; BLADDER CANCER; BREAST CANCER; CHROMOSOME 11Q; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE MAPPING; GENE SEQUENCE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; NEOPLASM; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 11; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84873717467     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22037     Document Type: Article

References (241)

1. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. 1998. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273: 28238-28246.
2. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R. 2000. Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem 275: 12041-12050.
3. Adelaide J, Monges G, Derderian C, Seitz JF, Birnbaum D. 1995. Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer 71: 64-68.
4. Adnane J, Gaudray P, Simon MP, Simony-Lafontaine J, Jeanteur P, Theillet C. 1989. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 4: 1389-1395.
5. Ahnstrom M, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. 2005. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat 91: 145-151.
6. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G. 2004. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534-8540.
7. Alarcon-Vargas D, Zhang Z, Agarwal B, Challagulla K, Mani S, Kalpana GV. 2006. Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors. Oncogene 25: 722-734.
8. Alavi S, Namazie A, Calcaterra TC, Wang MB, Srivatsan ES. 1999. Clinical application of fluorescence in situ hybridization for chromosome 11q13 analysis in head and neck cancer. Laryngoscope 109: 874-879.
9. Albertson DG. 2006. Gene amplification in cancer. Trends Genet 22: 447-455.
10. Ali IU, Merlo G, Callahan R, Lidereau R. 1989. The amplification unit on chromosome 11q13 in aggressive primary human breast tumors entails the bcl-1, int-2 and hst loci. Oncogene 4: 89-92.
11. Altinisik J, Karateke A, Coksuer H, Ulutin T, Buyru N. 2010. Expression of EMSY gene in sporadic ovarian cancer. Mol Biol Rep 38: 359-363.
12. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR, Weinstein IB. 1997. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57: 1569-1574.
13. Ashworth A, Bernards R. 2010. Using functional genetics to understand breast cancer biology. Cold Spring Harb Perspect Biol 2: a003327.
14. Ashworth A, Lord CJ, Reis-Filho JS. 2011. Genetic interactions in cancer progression and treatment. Cell 145: 30-38.
15. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, Kumar R. 2004. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 279: 1422-1428.
16. Balazs M, Adam Z, Treszl A, Begany A, Hunyadi J, Adany R. 2001. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 46: 222-232.
17. Barnes DM. 1997. Cyclin D1 in mammary carcinoma. J Pathol 181: 267-269.
18. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. 1994. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57: 353-361.
19. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J. 1995. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 55: 949-956.
20. Bast RCJr., Mills GB. 2010. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28: 3545-3548.
21. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. 1998. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58: 2170-2175.
22. Bautista S, Theillet C. 1998. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer 22: 268-277.
23. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, Kelley PM, Pebusque MJ, Theillet C, Birnbaum D, Gaudray P. 1997. Detailed map of a region commonly amplified at 11q13->q14 in human breast carcinoma. Cytogenet Cell Genet 79: 125-131.
24. Bentires-Alj M, Gil SG, Chan R, Wang ZC, Wang Y, Imanaka N, Harris LN, Richardson A, Neel BG, Gu H. 2006. A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 12: 114-121.
25. Benusiglio PR, Lesueur F, Luccarini C, McIntosh J, Luben RN, Smith P, Dunning A, Easton DF, Ponder BA, Pharoah PD. 2005. Common variation in EMSY and risk of breast and ovarian cancer: A case-control study using HapMap tagging SNPs. BMC Cancer 5: 81.
26. Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V, Vallot C, Pierron G, Radvanyi F, Delattre O. 2008. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 68: 7165-7175.
27. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
28. Bhojani MS, Chen G, Ross BD, Beer DG, Rehemtulla A. 2005. Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle 4: 1478-1481.
29. Bieche I, Olivi M, Nogues C, Vidaud M, Lidereau R. 2002. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 86: 580-586.
30. Biliran H, Jr., Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH, Liao JD. 2005. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 11: 6075-6086.
31. Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, Langerod A, Han W, Noh DY, Jeffrey SS, Huntsman DG, Borresen-Dale AL, Pollack JR. 2010. Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 29: 774-779.
32. Bokoch GM. 2003. Biology of the p21-activated kinases. Annu Rev Biochem 72: 743-781.
33. Bolzer A, Kreth G, Solovei I, Koehler D, Saracoglu K, Fauth C, Muller S, Eils R, Cremer C, Speicher MR, Cremer T. 2005. Three-dimensional maps of all chromosomes in human male fibroblast nuclei and prometaphase rosettes. PLoS Biol 3: e157.
34. Borg A, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Olsson H, Killander D, McGurie WL. 1991. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer 63: 136-142.
35. Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. 2007. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26: 6997-7005.
36. Bringuier PP, Tamimi Y, Schuuring E, Schalken J. 1996. Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene 12: 1747-1753.
37. Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A. 2011. Functional viability profiles of breast cancer. Cancer Discov 1: 260-273.
38. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D. 2006. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100: 264-270.
39. Brown LA, Kalloger SE, Miller MA, Shih Ie M, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG. 2008. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 47: 481-489.
40. Brown LA, Johnson K, Leung S, Bismar TA, Benitez J, Foulkes WD, Huntsman DG. 2010. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Res Treat 121: 347-354.
41. Brummer T, Schramek D, Hayes VM, Bennett HL, Caldon CE, Musgrove EA, Daly RJ. 2006. Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem 281: 626-637.
42. Burnworth B, Popp S, Stark HJ, Steinkraus V, Brocker EB, Hartschuh W, Birek C, Boukamp P. 2006. Gain of 11q/cyclin D1 overexpression is an essential early step in skin cancer development and causes abnormal tissue organization and differentiation. Oncogene 25: 4399-4412.
43. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. 2005. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12( Suppl 1): S47-S59.
44. Callagy G, Pharoah P, Chin SF, Sangan T, Daigo Y, Jackson L, Caldas C. 2005. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 205: 388-396.
45. Campbell DH, deFazio A, Sutherland RL, Daly RJ. 1996. Expression and tyrosine phosphorylation of EMS1 in human breast cancer cell lines. Int J Cancer 68: 485-492.
46. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T, Stebbings LA, Leroy C, Edkins S, Hardy C, Teague JW, Menzies A, Goodhead I, Turner DJ, Clee CM, Quail MA, Cox A, Brown C, Durbin R, Hurles ME, Edwards PA, Bignell GR, Stratton MR, Futreal PA. 2008. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 40: 722-729.
47. Carneiro A, Isinger A, Karlsson A, Johansson J, Jonsson G, Bendahl PO, Falkenback D, Halvarsson B, Nilbert M. 2008. Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. BMC Cancer 8: 98.
48. Chavali GB, Ekblad CM, Basu BP, Brissett NC, Veprintsev D, Hughes-Davies L, Kouzarides T, Itzhaki LS, Doherty AJ. 2005. Crystal structure of the ENT domain of human EMSY. J Mol Biol 350: 964-973.
49. Chen YJ, Lin SC, Kao T, Chang CS, Hong PS, Shieh TM, Chang KW. 2004. Genome-wide profiling of oral squamous cell carcinoma. J Pathol 204: 326-332.
50. Chen G, Bhojani MS, Heaford AC, Chang DC, Laxman B, Thomas DG, Griffin LB, Yu J, Coppola JM, Giordano TJ, Lin L, Adams D, Orringer MB, Ross BD, Beer DG, Rehemtulla A. 2005. Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci USA 102: 12507-12512.
51. Chernoff KA, Bordone L, Horst B, Simon K, Twadell W, Lee K, Cohen JA, Wang S, Silvers DN, Brunner G, Celebi JT. 2009. GAB2 amplifications refine molecular classification of melanoma. Clin Cancer Res 15: 4288-4291.
52. Chin SF, Wang Y, Thorne NP, Teschendorff AE, Pinder SE, Vias M, Naderi A, Roberts I, Barbosa-Morais NL, Garcia MJ, Iyer NG, Kranjac T, Robertson JF, Aparicio S, Tavare S, Ellis I, Brenton JD, Caldas C. 2007. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 26: 1959-1970.
53. Chow HY, Jubb AM, Koch JN, Jaffer ZM, Stepanova D, Campbell DA, Duron SG, O'Farrell M, Cai Q, Klein-Szanto AJ, Gutkind JS, Hoeflich KP, Chernoff J. 2012. p21-activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res 72:5966-5975.
54. Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK. 2004. Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: Association with cyclin D1 amplification and survival. Diagn Mol Pathol 13: 172-182.
55. Clark ES, Brown B, Whigham AS, Kochaishvili A, Yarbrough WG, Weaver AM. 2009. Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene 28: 431-444.
56. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. 2010. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3: ra84.
57. Courjal F, Theillet C. 1997. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res 57: 4368-4377.
58. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. 1996. Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69: 247-253.
59. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C. 1997. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups. Cancer Res 57: 4360-4367.
60. Cousineau I, Belmaaza A. 2011. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: Implications for chromosomal instability/recombination syndromes as checkpoint diseases. Mol Genet Genomics 285: 325-340.
61. Croucher DR, Rickwood D, Tactacan CM, Musgrove EA, Daly RJ. 2010. Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells. Mol Cell Biol 30: 5057-5070.
62. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S, Theillet C. 2000. Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 60: 1077-1083.
63. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147.
64. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Group M, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale A-L, Brenton JD, Tavaré S, Caldas C, Aparicio S. 2012. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486: 346-352.
65. Daly RJ. 2004. Cortactin signalling and dynamic actin networks. Biochem J 382( Part 1): 13-25.
66. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. 2010. Therapeutic CDK4/6 inhibition in breast cancer: Key mechanisms of response and failure. Oncogene 29: 4018-4032.
67. Dedes KJ, Lopez-Garcia MA, Geyer FC, Lambros MB, Savage K, Vatcheva R, Wilkerson P, Wetterskog D, Lacroix-Triki M, Natrajan R, Reis-Filho JS. 2010. Cortactin gene amplification and expression in breast cancer: A chromogenic in situ hybridisation and immunohistochemical study. Breast Cancer Res Treat 124: 653-666.
68. Dickson MA, Schwartz GK. 2009. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 16: 36-43.
69. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D, Peters G. 1995. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 90: 43-50.
70. Dimova I, Zaharieva B, Raicheva S, Milev I, Dimitrov R, Doganov N, Aleksandrov M, Todorov T, Toncheva D. 2004. Association of CyclinD1 copy number changes with histological type in ovarian tumors. Acta Oncol 43: 675-679.
71. Elsheikh S, Green AR, Aleskandarany MA, Grainge M, Paish CE, Lambros MB, Reis-Filho JS, Ellis IO. 2008. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 109: 325-335.
72. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Janne PA. 2010. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29: 2346-2356.
73. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. 2009. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11: R77.
74. Fleuren ED, O'Toole S, Millar EK, McNeil C, Lopez-Knowles E, Boulghourjian A, Croucher DR, Schramek D, Brummer T, Penninger JM, Sutherland RL, Daly RJ. 2010. Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. Int J Cancer 127: 1486-1492.
75. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. 2004. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3: 1427-1438.
76. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, Beger HG. 1997. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57: 1634-1637.
77. Garapaty S, Xu CF, Trojer P, Mahajan MA, Neubert TA, Samuels HH. 2009. Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation. J Biol Chem 284: 7542-7552.
78. Garg A, Aggarwal BB. 2002. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16: 1053-1068.
79. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH. 2012. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
80. Geradts J, Ingram CD. 2000. Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. Mod Pathol 13: 945-953.
81. Gibcus JH, Menkema L, Mastik MF, Hermsen MA, de Bock GH, van Velthuysen ML, Takes RP, Kok K, Alvarez Marcos CA, van der Laan BF, van den Brekel MW, Langendijk JA, Kluin PM, van der Wal JE, Schuuring E. 2007. Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res 13: 6257-6266.
82. Gibcus JH, Mastik MF, Menkema L, de Bock GH, Kluin PM, Schuuring E, van der Wal JE. 2008. Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer 98: 950-955.
83. Glatz-Krieger K, Pache M, Tapia C, Fuchs A, Savic S, Glatz D, Mihatsch M, Meyer P. 2006. Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. Virchows Arch 449: 328-333.
84. Gollin SM. 2001. Chromosomal alterations in squamous cell carcinomas of the head and neck: Window to the biology of disease. Head Neck 23: 238-253.
85. Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M, Rosfjord EC, Rabindran SK. 2006. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 95: 185-194.
86. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.
87. Hickinson DM, Marshall GB, Beran GJ, Varella-Garcia M, Mills EA, South MC, Cassidy AM, Acheson KL, McWalter G, McCormack RM, Bunn PA, French T, Graham A, Holloway BR, Hirsch FR, Speake G. 2009. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin Transl Sci 2: 183-192.
88. Hirokawa Y, Arnold M, Nakajima H, Zalcberg J, Maruta H. 2005. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther 4: 956-960.
89. Hofman P, Butori C, Havet K, Hofman V, Selva E, Guevara N, Santini J, Van Obberghen-Schilling E. 2008. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: Comparison with epidermal growth factor receptor status. Br J Cancer 98: 956-964.
90. Holland DG, Burleigh A, Git A, Goldgraben MA, Perez-Mancera PA, Chin SF, Hurtado A, Bruna A, Ali HR, Greenwood W, Dunning MJ, Samarajiwa S, Menon S, Rueda OM, Lynch AG, McKinney S, Ellis IO, Eaves CJ, Carroll JS, Curtis C, Aparicio S, Caldas C. 2011. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med 3: 167-180.
91. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G. 2006. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 98: 671-680.
92. Holm K, Staaf J, Jonsson G, Vallon-Christersson J, Gunnarsson H, Arason A, Magnusson L, Barkardottir RB, Hegardt C, Ringner M, Borg A. 2012. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours. Breast Cancer Res Treat 133: 583-594.
93. Horst B, Gruvberger-Saal SK, Hopkins BD, Bordone L, Yang Y, Chernoff KA, Uzoma I, Schwipper V, Liebau J, Nowak NJ, Brunner G, Owens D, Rimm DL, Parsons R, Celebi JT. 2009. Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol 174: 1524-1533.
94. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Schuuring E, Yu DS, Venkitaraman A, Ponder B, Doherty A, Aparicio S, Bentley D, Theillet C, Ponting CP, Caldas C, Kouzarides T. 2003. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115: 523-535.
95. Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, Daly RJ, Seshadri R, Sutherland RL. 1997. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene 15: 1617-1623.
96. Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OW, Campbell DH, Cornish AL, McClelland RA, Daly RJ, Forbes JF, Blamey RW, Musgrove EA, Robertson JF, Nicholson RI, Sutherland RL. 1998. EMS1 gene expression in primary breast cancer: Relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 17: 1053-1059.
97. Hui AB, Or YY, Takano H, Tsang RK, To KF, Guan XY, Sham JS, Hung KW, Lam CN, van Hasselt CA, Kuo WL, Gray JW, Huang DP, Lo KW. 2005. Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 65: 8125-8133.
98. Iorns E, Lord CJ, Turner N, Ashworth A. 2007. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6: 556-568.
99. Ishizuka T, Tanabe C, Sakamoto H, Aoyagi K, Maekawa M, Matsukura N, Tokunaga A, Tajiri T, Yoshida T, Terada M, Sasaki H. 2002. Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH. Biochem Biophys Res Commun 296: 152-155.
100. Janssen JW, Vaandrager JW, Heuser T, Jauch A, Kluin PM, Geelen E, Bergsagel PL, Kuehl WM, Drexler HG, Otsuki T, Bartram CR, Schuuring E. 2000. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood 95: 2691-2698.
101. Janssen JW, Cuny M, Orsetti B, Rodriguez C, Valles H, Bartram CR, Schuuring E, Theillet C. 2002a. MYEOV: A candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer. Int J Cancer 102: 608-614.
102. Janssen JW, Imoto I, Inoue J, Shimada Y, Ueda M, Imamura M, Bartram CR, Inazawa J. 2002b. MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas. J Hum Genet 47: 460-464.
103. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. 1992. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52: 2980-2983.
104. Jiang L, Chen RS, Li JC. 2006. [siRNA-cyclin D1 inhibit cell proliferation in breast cancer MCF-7 cell line]. Fen Zi Xi Bao Sheng Wu Xue Bao 39: 118-122.
105. Jiang L, Zeng X, Yang H, Wang Z, Shen J, Bai J, Zhang Y, Gao F, Zhou M, Chen Q. 2008. Oral cancer overexpressed 1 (ORAOV1): A regulator for the cell growth and tumor angiogenesis in oral squamous cell carcinoma. Int J Cancer 123: 1779-1786.
106. Jiang L, Zeng X, Wang Z, Ji N, Zhou Y, Liu X, Chen Q. 2010. Oral cancer overexpressed 1 (ORAOV1) regulates cell cycle and apoptosis in cervical cancer HeLa cells. Mol Cancer 9: 20.
107. Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G. 2005. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65: 8009-8016.
108. Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, Gere S, Kageyama S, Fukuoka J, Nagata T, Tsukada K, Dunn BK, Wakefield LM, Lee MP. 2009. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res 69: 7357-7365.
109. Kaelin WG, Jr. 2005. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689-698.
110. Kang JU, Koo SH. 2012. ORAOV1 is a probable target within the 11q13.3 amplicon in lymph node metastases from gastric adenocarcinoma. Int J Mol Med 29: 81-87.
111. Kao J, Pollack JR. 2006. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 45: 761-769.
112. Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Kubista E, Birnbaum D, Gaudray P, Theillet C. 1994. Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer 9: 42-48.
113. Karlsson E, Waltersson MA, Bostner J, Perez-Tenorio G, Olsson B, Hallbeck AL, Stal O. 2011. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer 50: 775-787.
114. Ke Y, Wu D, Princen F, Nguyen T, Pang Y, Lesperance J, Muller WJ, Oshima RG, Feng GS. 2007. Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene 26: 4951-4960.
115. Kelley LC, Hayes KE, Ammer AG, Martin KH, Weed SA. 2011. Revisiting the ERK/Src cortactin switch. Commun Integr Biol 4: 205-207.
116. Kirkegaard T, Nielsen KV, Jensen LB, Campbell FM, Muller S, Tovey SM, Brown S, Cooke TG, Bartlett JM. 2008. Genetic alterations of CCND1 and EMSY in breast cancers. Histopathology 52: 698-705.
117. Komatsu Y, Hibi K, Kodera Y, Akiyama S, Ito K, Nakao A. 2006. TAOS1, a novel marker for advanced esophageal squamous cell carcinoma. Anticancer Res 26: 2029-2032.
118. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. 2010. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28: 3555-3561.
119. Kothari V, Mulherkar R. 2012. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma. Anticancer Res 32: 121-128.
120. Koziczak M, Holbro T, Hynes NE. 2004. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23: 3501-3508.
121. Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, Albertson DG. 2009. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Oncogene 28: 1892-1903.
122. Kyomoto R, Kumazawa H, Toda Y, Sakaida N, Okamura A, Iwanaga M, Shintaku M, Yamashita T, Hiai H, Fukumoto M. 1997. Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma. Int J Cancer 74: 576-581.
123. Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, Capparelli C, Giordano C, Giordano F, Maggiolini M, Ando S. 2010. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells-Identification of a novel androgen response element. Nucleic Acids Res 38: 5351-5365.
124. Lazar V, Ecsedi S, Szollosi AG, Toth R, Vizkeleti L, Rakosy Z, Begany A, Adany R, Balazs M. 2009. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma. Mod Pathol 22: 1367-1378.
125. Lee YM, Sicinski P. 2006. Targeting cyclins and cyclin-dependent kinases in cancer: Lessons from mice, hopes for therapeutic applications in human. Cell Cycle 5: 2110-2114.
126. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, Ha C, Johnson S, Kennemer MI, Mohan S, Nazarenko I, Watanabe C, Sparks AB, Shames DS, Gentleman R, de Sauvage FJ, Stern H, Pandita A, Ballinger DG, Drmanac R, Modrusan Z, Seshagiri S, Zhang Z. 2010. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465: 473-477.
127. Lehn S, Tobin NP, Berglund P, Nilsson K, Sims AH, Jirstrom K, Harkonen P, Lamb R, Landberg G. 2010. Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol 177: 2886-2897.
128. Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M. 2006. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6: 245.
129. Leyden J, Murray D, Moss A, Arumuguma M, Doyle E, McEntee G, O'Keane C, Doran P, MacMathuna P. 2006. Net1 and Myeov: Computationally identified mediators of gastric cancer. Br J Cancer 94: 1204-1212.
130. Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, Lisanti MP, Katiyar S, Pestell RG. 2006a. Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res 66: 9986-9994.
131. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA, Dye C, Yang J, Dai M, Ju X, Zhang X, Li A, Burbelo P, Stanley ER, Pestell RG. 2006b. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 26: 4240-4256.
132. Lidereau R, Callahan R, Dickson C, Peters G, Escot C, Ali IU. 1988. Amplification of the int-2 gene in primary human breast tumors. Oncogene Res 2: 285-291.
133. Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MT, van de Vijver MJ, Wesseling J, Nederlof PM, Rodenhuis S. 2011. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol 22: 870-876.
134. Liu F, Li X, Wang C, Cai X, Du Z, Xu H, Li F. 2009a. Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. Int J Cancer 125: 2511-2519.
135. Liu HS, Lu HH, Lui MT, Yu EH, Shen W, Chen YP, Chang KW, Tu HF. 2009b. Detection of copy number amplification of cyclin D1 (CCND1) and cortactin (CTTN) in oral carcinoma and oral brushed samples from areca chewers. Oral Oncol 45: 1032-1036.
136. Lukas J, Bartkova J, Bartek J. 1996. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 16: 6917-6925.
137. Lundberg AS, Weinberg RA. 1998. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753-761.
138. Lundgren K, Holm K, Nordenskjold B, Borg A, Landberg G. 2008. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res 10: R81.
139. Luo ML, Shen XM, Zhang Y, Wei F, Xu X, Cai Y, Zhang X, Sun YT, Zhan QM, Wu M, Wang MR. 2006. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 66: 11690-11699.
140. Lynch DK, Winata SC, Lyons RJ, Hughes WE, Lehrbach GM, Wasinger V, Corthals G, Cordwell S, Daly RJ. 2003. A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem 278: 21805-21813.
141. Mahlamaki EH, Barlund M, Tanner M, Gorunova L, Hoglund M, Karhu R, Kallioniemi A. 2002. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 35: 353-358.
142. Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS. 2008. The genomic profile of HER2-amplified breast cancers: The influence of ER status. J Pathol 216: 399-407.
143. McDermott U, Downing JR, Stratton MR. 2011. Genomics and the continuum of cancer care. N Engl J Med 364: 340-350.
144. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW, Horne CH. 1995. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11: 885-891.
145. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J. 2005. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 65: 8085-8089.
146. Menard RE, Jovanovski AP, Mattingly RR. 2005. Active p21-activated kinase 1 rescues MCF10A breast epithelial cells from undergoing anoikis. Neoplasia 7: 638-645.
147. Meredith SD, Levine PA, Burns JA, Gaffey MJ, Boyd JC, Weiss LM, Erickson NL, Williams ME. 1995. Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg 121: 790-794.
148. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalck C, De Paepe A, Versteeg R, Eggert A, Laureys G, Van Roy N, Speleman F. 2007. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 46: 1098-1108.
149. Mira A, Isella C, Renzulli T, Cantarella D, Martelli ML, Medico E. 2009. The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer. Oncogene 28: 4444-4455.
150. Modi H, Li L, Chu S, Rossi J, Yee JK, Bhatia R. 2011. Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia 25: 305-312.
151. Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN. 2003. Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer 36: 242-249.
152. Moss AC, Lawlor G, Murray D, Tighe D, Madden SF, Mulligan AM, Keane CO, Brady HR, Doran PP, MacMathuna P. 2006. ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. Biochem Biophys Res Commun 345: 216-221.
153. Mottolese M, Orlandi G, Sperduti I, Merola R, Buglioni S, Di Benedetto A, Pinnaro P, Perracchio L, Venturo I, Cognetti F, Cianciulli A. 2007. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile. Am J Surg Pathol 31: 247-254.
154. Muller D, Millon R, Lidereau R, Engelmann A, Bronner G, Flesch H, Eber M, Methlin G, Abecassis J. 1994. Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinomas. Eur J Cancer B Oral Oncol 30B: 113-120.
155. Muller D, Millon R, Velten M, Bronner G, Jung G, Engelmann A, Flesch H, Eber M, Methlin G, Abecassis J. 1997. Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: Correlation with clinical outcome. Eur J Cancer 33: 2203-2210.
156. Natrajan R, Reis-Filho JS. 2011. Next-generation sequencing applied to molecular diagnostics. Expert Rev Mol Diagn 11: 425-444.
157. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, Hardisson D, Tutt A, Palacios J, Lord CJ, Buerger H, Ashworth A, Reis-Filho JS. 2009. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 15: 2711-2722.
158. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS. 2010. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 121: 575-589.
159. Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerod A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS. 2012. Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res 14: R53.
160. Newton K, Harris AW, Bath ML, Smith KG, Strasser A. 1998. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 17: 706-718.
161. Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, Sharp S, Chaplin T, Xue L, McIntyre A, Shan L, Powles T, Oliver RT, Young BD, Shipley J, Berney DM, Joel SP, Lu YJ. 2010. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol 176: 2607-2615.
162. Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T, Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H, Hoeflich KP. 2011. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci USA 108: 7177-7182.
163. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. 2003. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78: 323-335.
164. Patel AS, Schechter GL, Wasilenko WJ, Somers KD. 1998. Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene 16: 3227-3232.
165. Paterson AL, Pole JC, Blood KA, Garcia MJ, Cooke SL, Teschendorff AE, Wang Y, Chin SF, Ylstra B, Caldas C, Edwards PA. 2007. Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event. Genes Chromosomes Cancer 46: 427-439.
166. Pavey S, Zuidervaart W, van Nieuwpoort F, Packer L, Jager M, Gruis N, Hayward N. 2006. Increased p21-activated kinase-1 expression is associated with invasive potential in uveal melanoma. Melanoma Res 16: 285-296.
167. Pelosio P, Barbareschi M, Bonoldi E, Marchetti A, Verderio P, Caffo O, Bevilacqua P, Boracchi P, Buttitta F, Barbazza R, Dalla Palma P, Gasparini G. 1996. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 7: 695-703.
168. Peng Z, Luo HW, Yuan Y, Shi J, Huang SF, Li CL, Cao WX, Huang ZG, Feng WL. 2011. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes. Oncol Rep 25: 1381-1388.
169. Perisanidis C, Perisanidis B, Wrba F, Brandstetter A, El Gazzar S, Papadogeorgakis N, Seemann R, Ewers R, Kyzas PA, Filipits M. 2012. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 41: 40-46.
170. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. 1998. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 18: 4499-4508.
171. Prapinjumrune C, Morita K, Kuribayashi Y, Hanabata Y, Shi Q, Nakajima Y, Inazawa J, Omura K. 2010. DNA amplification and expression of FADD in oral squamous cell carcinoma. J Oral Pathol Med 39: 525-532.
172. Raouf A, Brown L, Vrcelj N, To K, Kwok W, Huntsman D, Eaves CJ. 2005. Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst 97: 1302-1306.
173. Reis-Filho JS, Pusztai L. 2011. Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 378: 1812-1823.
174. Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, Dowsett M. 2006a. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: An immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 19: 999-1009.
175. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, Weber B, Hardisson D, Schmitt FC, Palacios J, Lakhani SR, Ashworth A. 2006b. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12: 6652-6662.
176. Rodrigo JP, Garcia LA, Ramos S, Lazo PS, Suarez C. 2000. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 6: 3177-3182.
177. Rodrigo JP, Garcia-Carracedo D, Garcia LA, Menendez S, Allonca E, Gonzalez MV, Fresno MF, Suarez C, Garcia-Pedrero JM. 2009. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol 217: 516-523.
178. Rodriguez C, Hughes-Davies L, Valles H, Orsetti B, Cuny M, Ursule L, Kouzarides T, Theillet C. 2004. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 10: 5785-5791.
179. Roovers K, Assoian RK. 2000. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22: 818-826.
180. Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head JA, Chen L, Varella-Garcia M, Sacks PG, Frederick B, Raben D, Weed SA. 2006. Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 66: 8017-8025.
181. Roy PG, Pratt N, Purdie CA, Baker L, Ashfield A, Quinlan P, Thompson AM. 2010. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Int J Cancer 127: 355-360.
182. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. 2010. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 10: 59-64.
183. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC. 2002. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62: 3200-3206.
184. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H. 2003. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 163: 985-992.
185. Schuuring E. 1995. The involvement of the chromosome 11q13 region in human malignancies: Cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene 159: 83-96.
186. Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FB, Devilee P, Cornelisse CJ, van de Vijver MJ, Mooi WJ, Michalides RJAM. 1992. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 52: 5229-5234.
187. Schwab M. 1998. Amplification of oncogenes in human cancer cells. Bioessays 20: 473-479.
188. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. 2008. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442-2449.
189. Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ, Sutherland RL. 1996. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2: 1177-1184.
190. Shan J, Zhao W, Gu W. 2009. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell 36: 469-476.
191. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, Sakiyama T, Matsuno Y, Tsuchiya R, Kanai Y, Kondo T, Imoto I, Inazawa J, Hirohashi S. 2005. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: Its association with clinicopathologic features. Clin Cancer Res 11: 6177-6185.
192. Shrestha Y, Schafer EJ, Boehm JS, Thomas SR, He F, Du J, Wang S, Barretina J, Weir BA, Zhao JJ, Polyak K, Golub TR, Beroukhim R, Hahn WC. 2012. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene 31: 3397-3408.
193. Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, Lonigro A, Adelaide J, Baudelet E, Esteyries S, Wicinski J, Audebert S, Charafe-Jauffret E, Jacquemier J, Lopez M, Borg JP, Sotiriou C, Popovici C, Bertucci F, Birnbaum D, Chaffanet M, Ginestier C. 2011. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 3: 153-166.
194. Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, Tam KF, Ngan HY, Chan QK, Chan DC, Chan KY, Cheung AN. 2010. Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: Effects on prognosis and cell invasion. Int J Cancer 127: 21-31.
195. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL. 2008. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 7: 2876-2883.
196. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, Eyfjord JE. 2009. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 11: R47.
197. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, Landberg G. 2004. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90: 1942-1948.
198. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerod A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Borresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR. 2009. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462: 1005-1010.
199. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerod A, Lee MT, Shen CY, Tee BT, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van 't Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Borresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR. 2012. The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404.
200. Stratton MR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458: 719-724.
201. Sugahara K, Michikawa Y, Ishikawa K, Shoji Y, Iwakawa M, Shibahara T, Imai T. 2011. Combination effects of distinct cores in 11q13 amplification region on cervical lymph node metastasis of oral squamous cell carcinoma. Int J Oncol 39: 761-769.
202. Takano Y, Takenaka H, Kato Y, Masuda M, Mikami T, Saegusa M, Okayasu I. 1999. Cyclin D1 overexpression in invasive breast cancers: Correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity. J Cancer Res Clin Oncol 125: 505-512.
203. Takata M, Goto Y, Ichii N, Yamaura M, Murata H, Koga H, Fujimoto A, Saida T. 2005. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. J Invest Dermatol 125: 318-322.
204. Takes RP, Baatenburg de Jong RJ, Schuuring E, Hermans J, Vis AA, Litvinov SV, van Krieken JH. 1997. Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 123: 412-419.
205. Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M. 1994. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: Association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene 9: 2663-2674.
206. Tashiro E, Maruki H, Minato Y, Doki Y, Weinstein IB, Imoto M. 2003. Overexpression of cyclin D1 contributes to malignancy by up-regulation of fibroblast growth factor receptor 1 via the pRB/E2F pathway. Cancer Res 63: 424-431.
207. Tetsu O, McCormick F. 2003. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3: 233-245.
208. Theillet C, Le Roy X, De Lapeyriere O, Grosgeorges J, Adnane J, Raynaud SD, Simony-Lafontaine J, Goldfarb M, Escot C, Birnbaum D. 1989. Amplification of FGF-related genes in human tumors: Possible involvement of HST in breast carcinomas. Oncogene 4: 915-922.
209. Tibbetts MD, Zheng L, Lenardo MJ. 2003. The death effector domain protein family: Regulators of cellular homeostasis. Nat Immunol 4: 404-409.
210. Timpson P, Lynch DK, Schramek D, Walker F, Daly RJ. 2005. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res 65: 3273-3280.
211. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. 2007. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 67: 9304-9314.
212. Tourneur L, Chiocchia G. 2010. FADD: A regulator of life and death. Trends Immunol 31: 260-269.
213. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J, Yoshida T, Sakamoto H, Terada M, Sugimura T. 1989a. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49: 3104-3108.
214. Tsuda T, Tahara E, Kajiyama G, Sakamoto H, Terada M, Sugimura T. 1989b. High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res 49: 5505-5508.
215. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, Ashworth A, van de Vijver MJ, Reis-Filho JS. 2010a. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29: 2013-2023.
216. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A. 2010b. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085-2094.
217. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, Chernoff J, Hung MC, Kumar R. 2000. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 275: 36238-36244.
218. van Hattem WA, Carvalho R, Li A, Offerhaus GJ, Goggins M. 2008. Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. Int J Clin Exp Pathol 1: 343-351.
219. Varmus H, Bishop JM. 1986. Biochemical mechanisms of oncogene activity: Proteins encoded by oncogenes. Introduction. Cancer Surv 5: 153-158.
220. Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
221. Walsh CM, Wen BG, Chinnaiyan AM, O'Rourke K, Dixit VM, Hedrick SM. 1998. A role for FADD in T cell activation and development. Immunity 8: 439-449.
222. Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R. 2006. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 25: 2931-2936.
223. Weaver AM. 2008. Cortactin in tumor invasiveness. Cancer Lett 265: 157-166.
224. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. 2012. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 9: 58-64.
225. Weinberg RA. 1996. The molecular basis of carcinogenesis: Understanding the cell cycle clock. Cytokines Mol Ther 2: 105-110.
226. Weinstein IB, Joe AK. 2006. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457.
227. Weinstein IB, Joe A. 2008. Oncogene addiction. Cancer Res 68: 3077-3080; discussion 3080.
228. Wilcken NR, Prall OW, Musgrove EA, Sutherland RL. 1997. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3: 849-854.
229. Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS. 2011. Functional characterisation of EMSY gene amplification in human cancer. J Pathol 225: 29-42.
230. Williams ME, Gaffey MJ, Weiss LM, Wilczynski SP, Schuuring E, Levine PA. 1993. Chromosome 11Q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 119: 1238-1243.
231. Wohrle FU, Daly RJ, Brummer T. 2009. Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal 7: 22.
232. Xavier FC, Rodini CO, Paiva KB, Destro MF, Severino P, Moyses RA, Tajara EH, Nunes FD. 2012. ORAOV1 is amplified in oral squamous cell carcinoma. J Oral Pathol Med 41: 54-60.
233. Yang Y, Wu J, Demir A, Castillo-Martin M, Melamed RD, Zhang G, Fukunaga-Kanabis M, Perez-Lorenzo R, Zheng B, Silvers DN, Brunner G, Wang S, Rabadan R, Cordon-Cardo C, Celebi JT. 2012. GAB2 induces tumor angiogenesis in NRAS-driven melanoma. Oncogene; DOI: 10.1038/onc.2012.1367. [Epub ahead of print on 27/08/2012].
234. Yi C, Maksimoska J, Marmorstein R, Kissil JL. 2010. Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer. Biochem Pharmacol 80: 683-689.
235. Yuan BZ, Zhou X, Zimonjic DB, Durkin ME, Popescu NC. 2003. Amplification and overexpression of the EMS 1 oncogene, a possible prognostic marker, in human hepatocellular carcinoma. J Mol Diagn 5: 48-53.
236. Zaharieva BM, Simon R, Diener PA, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Hering F, Schonenberger A, Flury R, Jager P, Fehr JL, Mihatsch MJ, Gasser T, Sauter G, Toncheva DI. 2003. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 201: 603-608.
237. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. 1998. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392: 296-300.
238. Zhang J, Kabra NH, Cado D, Kang C, Winoto A. 2001. FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery. J Biol Chem 276: 29815-29818.
239. Zhang J, Zhang D, Hua Z. 2004. FADD and its phosphorylation. IUBMB Life 56: 395-401.
240. Zhou DJ, Ahuja H, Cline MJ. 1989. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105-108.
241. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. 1997. CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415.